Metallothionein protects islets from hypoxia and extends islet graft survival by scavenging most kinds of reactive oxygen species.
Islet transplantation is a promising therapy for Type 1 diabetes, but many attempts have failed due to early graft hypoxia or immune rejection, which generate reactive oxygen species (ROS). In the current study, we determined that transgenic overexpression of the antioxidant metallothionein (MT) in pancreatic beta cells provided broad resistance to oxidative stress by scavenging most kinds of ROS including H2O2, peroxynitrite radical released from streptozotocin, 3-morpholinosydnonimine (SIN-1), and superoxide radical produced by xanthine/xanthine oxidase. MT also reduced nitric oxide-induced beta cell death. A direct test of hypoxia/reperfusion sensitivity was made by exposing FVB and MT islets to hypoxia (1% O2). MT markedly reduced ROS production and improved islet cell survival. Because MT protected beta cells from a broad spectrum of ROS and from hypoxia, we considered it to be an ideal candidate for improving islet transplantation. We first tested syngeneic transplantation by implanting islets under the kidney capsule of the same strain, FVB mice, thereby eliminating the immune rejection component. Under these conditions, MT islets maintained much greater insulin content than control islets. Allotransplantation was then tested. MT transgenic and normal FVB islets were implanted under the kidney capsule of BALB/c mice that were previously treated with streptozotocin to induce diabetes. We found that MT islets extended the duration of euglycemia 2-fold longer than nontransgenic islets. The benefit of MT was due to protection from ROS since nitrotyrosine staining, an indicator of free radical damage, was much lower in MT grafts than in FVB grafts. The time course of protection suggested that the major mode of MT action may have been protection from hypoxia or hypoxia/reperfusion. These data demonstrate that treatment with a broad spectrum antioxidant protects islets from ROS damage such as that produced during the early phase of islet transplantation.
Li
Xiaoyan
X
Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
Chen
Hainan
H
Epstein
Paul N
PN
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D015687:Cell Hypoxia / Q000502:physiology*; D016166:Free Radical Scavengers / Q000494:pharmacology*; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D016381:Islets of Langerhans Transplantation / Q000502:physiology*; D008668:Metallothionein / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D013997:Time Factors; D014184:Transplantation, Homologous / Q000502:physiology; D014185:Transplantation, Isogeneic
D001786:Blood Glucose; D016166:Free Radical Scavengers; D008668:Metallothionein